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Introduction
 Human papillomaviruses (HPV) are small, 
double stranded DNA viruses that belong to family 
papillomaviridae1. Papillomaviruses were first 
identified, cloned and sequenced from cervical tumor 
specimens and were subsequently established as 
important causative agents for development of cervical 
cancer, the discovery which was honored by conferring 
Nobel Prize of Physiology and Medicine for the year 
2008 to its inventor Harald zurHausen2-6. Subsequent 
research demonstrated infection of papillomaviruses 
in cutaneous and mucosal tissues of the oral cavity, 
upper gastrointestinal tract, anogenital tract and skin 
of hands and feet7. These viral infections were also 
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found in other mammals but without any inter-species 
transmission. Papillomaviruses exhibit a high degree 
of specific cellular tropism for squamous epithelial 
cells and have been associated with various clinical 
manifestations ranging from benign hyperplastic 
epithelial proliferative innocuous lesions (warts, 
papillomas) to invasive cancer. These proliferative 
hyperplastic lesions can be cutaneous (skin warts) or 
can involve mucosal squamous epitheliam of genital 
tract, oral, pharynx, or esophagous. 
 At least 15 HPV types associated with malignancy 
of both genital tract and non-genital tract have been 
categorized as High Risk (HR) types (HPV 16, 18, 
31, 35, 39, 45, 51, 52, 56, 59, 66, 68, 69, 73 and 82), 
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whereas those associated with benign lesions such as 
genital and skin warts, as Low-Risk (LR) types (HPV 
6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108). More 
than 100 different HPV types have been described 
till date,  associated with infection of anogenital tract 
and other organ sites. Though epidemiological and 
molecular studies have established the casual relation 
of HPV infection with development of cervical 
cancer, a sizable number of studies also demonstrated 
associations of HPV infection with other cancers8. The 
majority of high-risk HPV types are associated with the 
development of cancer of uterine cervix, vagina, vulva, 
adenocarcinoma in women and anus, oro-pharynx, and 
esophagus in both men and women. Persistent infections 
with HR-HPVs have been identified as an essential 
although not sufficient factor in the pathogenesis of 
anogenital and other epithelial carcinomas9. HPV 
infection is also reported in skin cancer, lung cancer 
and in retinoblastoma10, but the frequency has been low 
in India. Though controversial, presence of HPV DNA 
sequences has also been reported in Breast cancer11. 
Presence of HPV in sites other than reproductive organs 
clearly indicates passage of the virus via routes other 
than sexual transmission, which are as yet unknown. 
 In view of diversity in HPV types and their 
association with different lesions with respect to their 
site, it is important to analyze the extent of prevalence 
of HPV infection in general and to determine HPV type-
specific association to cancers of different organ sites 
in particular. In an International Agency for Research 
in Cancer (IARC)-initiated study (Globocan 2002), to 
determine the global cancer incidence demonstrated 
about 5.17 per cent of all cancers can be attributed to HPV 
and cancer of anus is next to cancers of uterine cervix 
that show as high as 90 per cent cases attributed to HPV 
infection (Table I). Cancers of vulva, vagina, penis and 
oro-pharynx also show moderate HPV infection. Similar 
data on HPV prevalence in India where two promising 
HPV prophylactic vaccines against high-risk HPV type 
16 and 18 and low-risk HPV types 6 and 11 are going to 
be introduced soon is, however, highly fragmentary. In 
addition, majority of the available information is related 
with cancer of uterine cervix only and has been collected 
using variety of detection methods which have variable 
sensitivity and specificity and are susceptible to intra- 
and inter-laboratory variations. Since HPV vaccination 
will also affect the HPV-associated disease pattern 
other than cervix, in this article, we tried to present 
studies which analyzed presence of HPV infection in 
cancers of various organ sites (Table II). Though all 
these studies14-16,23,26,27,32,34,37-39,41,49 were performed using 
various technologies available at that time, and had 
considerable variations in results and these might have 
been carried out in a small subset of samples, yet they 
provide significant preliminary data on HPV prevalence 
in Indian population. 
Cancers of anogenital tract
Cancer of uterine cervix: Squamous cell carcinoma of 
the uterine cervix, a malignant cancer of the women 
develops through a defined series of pre-neoplastic 
lesions with increasing cellular dysplasia referred to as 
cervical intraepithelial neoplasia (CIN) that are graded 
CIN1, CIN2, or CIN3 depending upon the severity of the 
lesion50.  It is the second most common cancer among 
women worldwide. There were estimated 493,000 
new cases and 274,000 deaths due to cervical cancer 
in 2002 with more than 83 per cent cases occurring 
in developing countries12. In India, it is estimated 
that 132,000 new cases of cervical cancer and over 
75,000 deaths are reported annually. Proportionately 
a quarter of the global burden accounting to 27 per 
cent of total cervical cancer cases are reported from 
India while it houses only 16-17 per cent of world’s 
women population. Cancer of the cervix constitutes 
about 15-51 per cent of all female cancers and rates of 
age-standardized incidence range from 17.2 to 55 per 
100,000 women in different regions of India51.
 Infection of HPV 16/18 is estimated to account 
for more than 80 per cent of invasive cervical cancer 
Table I. Global incidence of  HPV attributable cancer in 2002: GLOBOCAN 200212,13
Gender-specific 
cancers
Human organ site HPV 
attribution 
(%)
Total cancers Attributable to 
HPV infection
Per cent of 
all cancers
HPV 16/18 
association (%)
Per cent of 
all cancers
Females Uterine cervix 100 492,800 492,800 4.54 344,900 (70) 3.18
Vulva, vagina 40 40,000 16,000 0.15 12,800 (80) 0.12
Males Penis 40 26,300 10,500 0.10 6600 (63) 0.06
In both Anus 90 30,400 27,300 0.25 25,100 (92) 0.23
Mouth 3 274,300 8200 0.08 7800 (95) 0.07
Oro-pharynx 12 52,100 6200 0.06 5500 (89) 0.05
All-sites 10,862,500 561,000 5.17 402,900 (72) 3.71
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including CIN3 and for 50 per cent of CIN2 lesions52. 
In India, 85-90 per cent cervical cancer cases are 
squamous cell carcinoma and the HPV 16 is the most 
prevalent type among them compared to other parts of 
the world where the proportion of HPV16 is much lower 
and ranges only upto 70 per cent when both HPV16 and 
18 are considered1, 53,54. In India, HPV type 16 alone in 
cervical cancer is 70-90 per cent while occurrence of 
HPV type 18 varies from 3 to 20 per cent. Other high-
risk HPV types such as HPV 45, 33, 35, 52, 58, 59, and 
73 have also been reported are rare and constitute only 
a minor group25-28. In a national HPV mapping study, 
prevalence of HPV type 16 was found to be highest 
in Chennai (88%), whereas it was very low in Jammu 
& Kashmir (14.2%)55. The possible reason for low 
prevalence of HPV infection in Jammu & Kashmir is 
possibly due to the practice of circumcision in Muslim 
population56. The age-wise prevalence of HPV and HR-
HPV16/18 infections among healthy female subjects 
from different geographical regions of India has also 
been reported26-28,49,57,58 . Interestingly, the peak of HPV 
infection, particularly HPV 16, appears to reach at later 
stage in third decade of sexual life at 26-35 years in 
Indian women in contrast to 18-25 years reported in 
western countries59,60.
Adenocarcinoma of uterine cervix: The adenocarcinoma 
of cervix originates adjacent to the squamous epithelial 
neoplastic lesions. Though majority cases of cervical 
cancer are squamous cell carcinomas (SCCs), 
adenocarcinoma of cervix also contributes to the 
overall burden of cancer of uterine cervix. The higher 
proportion of adenocarcinoma cases has been observed 
in those areas where incidence of cervical cancer is low 
and in some western countries it accounts for more than 
25 per cent of cervical cancer cases61. Unlike squamous 
cell carcinoma where HPV 16 contributes upto 70 per 
cent of cases, in adenocarcinoma, infection of HPV 18 
is reported to be more prevalent worldover (>86%)62,63. 
In contrast, only 10-15 per cent of cervical cancer cases 
in India are adenocarcinoma and HPV16 is the most 
prevalent type, though it is less frequent than what is 
found in the squamous cell carcinoma (42% vs 70-
90%). As compared to preferential occurrence of HPV 
18 in adenocarcinoma reported worldwide, only 17 per 
cent cases showed infection with HPV18 in India that 
too was present as co-infection with HPV1618, 64.
Cancer of vagina: Vaginal cancer is a less frequent 
cancer in women and the age standardized rate is 0.3-0.7 
per 100,000 worldwide13. The number of studies on the 
role of HPV infection and occurrence of vaginal cancer 
is limited and have analyzed only in fixed tissues for a 
few types of HPV65. Epidemiological studies indicate 
that the cancer of vagina resembles the cancer of 
uterine cervix and HPV DNA sequences are detected in 
majority of vaginal tumors and their precursor lesions. 
Like in cervical cancer HPV16 is the most prevalent 
Table II. Attribution of HPV infection in cancers of different organ sites in India
Organ site HPV prevalence 
(%)
Prevalence of HPV 
16/18 (%)
Detection methods HPV types References
A. Anogenital cancers
    Uterine Cervix 50-98* 60-90 SBH, ISH, PCR-TS, RLB, 
PCR-ELSIA,HCII
HPV16,18,31,33,35,39,45,51,
52,56,58,59,66,71,73,6,11
14-28
    Anus 0-22 22 PCR L1, PCR-TS, IHC HPV16, 18 29, 30
    Penis 30 30 PCR L1, PCR-TS HPV16, 18 30
    Ovary 0 0 PCR L1, PCR-TS HPV16, 18 30
B. Head and neck cancers
    Oral cavity 15-74 6-47 SBH, PCR L1, PCR-TS, 
PCR-Sequencing 
HPV16,18,6,11 31-38
    Esophagus 26.7 18.8 PCR L1, PCR-TS HPV16,18 39-41
    Larynx 30-70 30 (HPV 16), PCR L1, PCR-TS HPV16,18 42
    Naso-pharynx 38.8 ND IHC 43
C. Other cancers
    Lung 5 5 PCR L1, PCR-TS HPV16,18 44
    Urinary bladder 10-20 10-20 ISH, PCR HPV16 45
    Stomach 8.3 8.3 (HPV 16) PCR L1, PCR-TS HPV16,18 30
    Eye 0-17 ND IHC HPV16,18 30, 46
    Breast 0 0 SBH, RQ-PCR, HPV16,18 47, 48
ELISA, enzyme linked immunosorbent assay; HCII, hybrid capture II; ISH, in situ hybridization; PCR, polymerase chain reaction, PCR L1- 
HPV L1 Consensus PCR; PCR-TS- HPV type specific PCR; RQ-PCR, real time quantitative-PCR; SBH, Southern blot hybridization; RLB, 
reverse line blot hybridization; (PGMY), PCR-sequencing, ND-not determined
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type found in vaginal cancer66,67  and the frequency of 
HPV varies between 82 to 100 per cent of VAIN-3 and 
64 to 91 per cent in vaginal cancer65. 
 In India, the occurrence of vaginal cancer is low 
and vary between different geographical regions. 
According to cancer registries data among different 
places the age standardized rate of vaginal cancer 
varies from 1.4 per 100,000 in Pune to 0.3 in Bhopal68. 
The detection of HPV infection in vaginal cancer has 
not been reported in India and hence the information 
on the prevalence of HPV infection in cancer of vagina 
is not available.
Cancer of vulva: The worldwide ASRs of vulvar cancer 
lie between 0.5 and 1.5 per 100,000. The geographical 
pattern of vulvar cancer is not similar to cervical 
cancer and high rates are observed in several European 
populations (Scotland, Denmark, Spain, Italy), while 
it showed a low prevalence in sub-Saharan Africa, 
Southeast Asia, and Latin America13. Distinct subtypes 
like the warty and basoloid types have been recognized 
but majority of tumors are squamous cell carcinoma. 
Etiologically vulvar carcinomas are heterogeneous and 
thus the presence of HPV infection in invasive vulvar 
cancer cases varies69-71. Vulvar cancer with basaloid 
histopathology in young women is often associated with 
HPV69. HR-HPV types 16, 31 and 33 are the frequently 
detected types in vulvar cancer and its precursor 
lesions, VIN72. On the other hand, vulvar cancer with 
verrucus subtype and some cases of the precancerous 
lesions of vulvar intraepithelial neoplasia (VIN), are 
not associated with HPV infection73. In India, no report 
is available on the prevalence and type distribution of 
HPV infection in vulvar cancer.
Cancer of anus: Cancers of the anus are those arising 
in the anal canal and tumors of the external skin (anal 
margin) are classified along with skin cancers. The 
canal is lined in its upper part by colorectal-type of 
mucosa, and in its lower third by squamous epithelium, 
with specialized transitional zone epithelium in 
between. Therefore, cancers are predominantly 
SCCs, adenocarcinomas, or basaloid and cloacogenic 
carcinomas. In most populations SCC is twice more 
common in females than in males61. Incidence is 
specifically high among homosexual males and the 
risk is increased further by infection with HIV. Risk 
is also reported to increase by cigarette smoking, 
anal intercourse, and the number of lifetime sexual 
partners74. According to Cancer Registries of India, the 
observed incidence of anal cancer is higher in females 
than that of males in India61. The role of HPV infection 
in etiology of anal cancer has not been explored 
extensively in India. A study by Gupta et al29 showed 
presence of HPV 16/18 in 22 per cent cases out of 36 
anal cancer cases studied by immunohistochemical 
methods. On the other hand, analysis by consensus and 
type specific PCR revealed complete absence of HPV 
infection in 20 anal cancers studied30. The observed 
difference in the prevalence of HPV infection in anal 
cancer may be attributable partly to techniques used for 
HPV detection and partly because of low prevalence of 
anal sex in India. 
Cancer of penis: Globally penile cancer is rare cancer 
and accounts for less than 0.5 per cent of all cancers in 
men13. The concordance of cervical and penile cancer in 
married couples and geographical distribution of these 
cancers suggest that it shares a common etiology75. 
Serological studies have confirmed the role of HPV16 
and HPV18 in etiology of penile cancer and HPV DNA 
is detected in 40-50 per cent of penile cancers76. Cancer 
Registries have demonstrated that observed incidence 
rates of penile cancer are higher in India in comparison 
to western countries. 
 Although the incidence of penile cancer is higher 
in India, the role of HPV infection in the etiology of 
this cancer has not been very well studied. There is no 
comprehensive study that demonstrate prevalence and 
type distribution of HPV in penile carcinoma in India. 
In a small sample size (n=30) HPV 16 was detected in 
30 per cent of penile cancers30. In contrast, Gupta et al77 
using penile smears demonstrated HPV 16 infection in 
67 per cent (20/30) of male partners of women with 
invasive cervical cancer. It reiterates that HPV16 is the 
most frequent type found in penile cancer in India. As 
India harbors more than 1/4th of total global cervical 
cancer cases, the prevalence of penile cancer in male 
partners of women with cervical precancer and cancer 
could be higher. Therefore, an organized and regular 
screening of penile cancer is very important particularly 
in view of upcoming HPV vaccine trials in India. Man 
being the main host reservoir of HPV infection, it is 
important to give HPV vaccine to males thus creating 
herd immunity against the HR-HPV types responsible 
for the disease.
Ovarian cancer: Ovarian cancer is most commonly 
formed in the epithelial lining of the ovary resulting in 
epithelial ovarian cancer or in the egg cells resulting in 
a germ cell tumor. Ovarian cancer is the fifth leading 
cause of death from cancer in women and the leading 
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cause of death from gynecological cancer78. A woman 
has a lifetime risk of ovarian cancer of around 1.5 per 
cent. Primary squamous cell carcinoma of the ovary 
is rare, most cases represent malignant transformation 
of ovarian teratomas or are associated with preexisting 
Brenner tumor or ovarian endometriosis. The actual cause 
of ovarian cancer is unknown. There is an increased risk 
of ovarian cancer in older women and in those who have 
a first or second degree relative with the disease79,80. 
The role of HPV infection in etiology of ovarian cancer 
remains unclear and the results differ worldwide. Some 
studies have demonstrated that HR-HPV types 16 and 
18 play an important role in the development of ovarian 
cancer81 whereas some authors suggest that HPV is highly 
unlikely to play any causal role in the pathogenesis of 
epithelial ovarian neoplasia82. In India, the role of HPV 
infection in pathogenesis of ovarian carcinoma has not 
been explored. In a small study on the prevalence of HPV 
infection in 20 ovarian cancer biopsies using consensus 
and type specific PCR for high risk HPV types 16 and 
18 demonstrated complete absence of HPV infection in 
ovarian cancer in India30.
Head and neck cancers
Oral cancer: Oral Squamous Cell Carcinoma (OSCC) 
is the sixth most common cancer globally and accounts 
for approximately 5 per cent of all malignant tumors 
worldwide78. In India and South East Asia OSCC is 
the most common malignancy amounting up to 50 
per cent of all malignant tumors83. Although most 
of the OSCC is attributed to tobacco and alcohol 
consumption, a significant proportion of oral cancers 
have been demonstrated to contain anogenital HPV 
infection84. The high risk HPV type 16 tends to be the 
most predominant type detected in oral cancer9,84.
 The prevalence of HPV in oral cancer has been 
well documented in several studies from different 
geographical regions of India. However, the prevalence 
of HPV differs in different geographical regions within 
Indian subcontinent. The infection of HPV 16 is reported 
in 27 per cent of oral cancer from north India38 whereas 
from western part of the country it ranges from 25 to 
31 per cent34,37. Multiple HPV infection was observed 
in about 14 per cent of cases37. The reports of HPV 
prevalence in oral cancer from southern India seems 
to be highly variable. The overall frequency of HPV 
infection has been reported to be 74 per cent while 41 
per cent showed multiple HPV infection32. HPV type-
specific infection for HPV types 6, 11, 16 and 18 was 
found to be 13, 20, 42 and 47 per cent, respectively32. 
Cancer of esophagous: Esophageal Squamous 
Cell Carcinoma (ESCC) is highly divergent and 
demonstrates wide regional variation in incidence and 
causal associations in different geographical regions of 
the world61. Infection with HPV has been implicated as 
one of the possible etiological factors but occurrence 
of HPV infection is conflicting, varying from complete 
absence to detection of up to 60 to 70 per cent of HPV 
positivity mainly of HPV type 16 and 18 in the cancer 
biopsies85.
 In India, the incidence of esophageal carcinoma 
also differs from region to region and the association 
of HPV infection has been demonstrated in a number 
of studies. Agarwal et al39 reported a significantly 
higher number (63%) of esophageal cancer cases 
immunopositive for HPV16 E6 oncoprotein. In an 
interesting study carried out in esophageal cancer 
patients from three different high incidence geographic 
regions of India with different food habits, smoking, 
tobacco chewing and ethnicity showed significant 
difference in the frequency of HPV infection41. Of a 
total of 101 biopsy specimens of carcinoma esophagus 
analyzed, the frequency of HPV was found to be the 
highest (44%) in Dibrugarh followed by 33 per cent in 
Kashmir, but, no high-risk HPV could be detected in 
New Delhi patients (0%) which showed significantly a 
high frequency of p53 mutations as compared to that of 
the other two regions38.
Laryngeal carcinoma: Laryngeal cancer is the most 
common cancer of the upper aerodigestive tract. Age-
standardized incidence rates ranged from 2.5 to 17.1 
per 100,000 person-years at risk in men while 0.1 to 1.3 
per 100,000 person-years at risk in women. In European 
and Asian countries, most squamous cell carcinomas of 
the larynx result from an exposure to carcinogens, such 
as tobacco and alcohol, which cause diffuse mucosal 
changes. HPV has been found in a good proportion 
of laryngeal cancers86. A meta-analysis of 60 HNSCC 
specimens has demonstrated prevalence of HPV DNA 
in 24 per cent (ranges 0-100%) of laryngeal squamous 
cell carcinoma86. HPV 16 was accounted for the 69.2 
per cent whereas HPV 18 was found in 17 per cent of 
laryngeal carcinoma cases. In India, the prevalence 
of HPV infection was found in 34 per cent (15/44) of 
invasive laryngeal squamous cell carcinoma42. 
Nasopharyngeal carcinoma (NPC): Nasopharyngeal 
cancer is an uncontrolled growth of cells that begins 
in the nasopharynx, the passageway at the back of the 
nose. Nasopharyngeal carcinoma (NPC) is a common 
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cancer in Southeast Asia and is frequently associated 
with Epstein-Barr virus (EBV) infection. Recent 
studies have indicated HPV, particularly HPV31, is 
also found in a significant number of NPC cases. In 
India, prevalence of HPV infection was found in 38.8 
per cent (14/36) cases of NPC by immunohistochemical 
localization of HPV antigens, whereas 10 per cent 
(1/10) cases of adenoid lesions also showed presence 
of HPV43.  
Other cancers
Cancer of lung:  The malignant proliferation of lower 
respiratory tract epithelial cells results into development 
of lung cancer. Lung cancer is one of the most common 
form of malignancy worldwide and is the leading cause 
of cancer related deaths around the world including 
India. Smoking is considered to be one of the principal 
causes of lung cancer; however, genetic factors such 
as mutation or over-expression of oncogenes e.g., 
c-myc, erbB2, polymorphism in P450 (CYP1A1) 
and glutathione transferase M1 genes, functional 
inactivation of tumor suppressor genes eg, Rb, p16, 
p53 genes including p53 codon 72 polymorphism, and 
infection of specific types of human papillomaviruses, 
have been implicated with the development of lung 
cancer87,88.
 The reports on the association of HPV infection 
in lung cancer are not only rare but also controversial. 
Several authors have reported that HPV has no role 
to play in lung carcinogenesis, whereas others have 
observed a low frequency (4-18%) of specifically 
HPV18 infection in lung cancer. In contrast, a moderate 
to a very high frequency of HPV infection (30-79%) 
has been reported by others89,90. In India, a very low 
frequency (5%, 2/40) of only HPV18 infection has 
been observed but no other HPV types including most 
prevalent HPV16 were found in lung cancer44.
Cancer of urinary bladder:  Over 90 per cent of bladder 
cancers are transitional cell carcinomas, or cancers of the 
epithelial cell lining of the bladder, ureters and urethra. 
Though the exact causes are unknown, both genetic 
and environmental factors are responsible91. The role of 
HPV infections in the development of bladder cancers 
is unlikely as the most of the cases are transitional cell 
carcinomas in the developed world. Although some 
studies have demonstrated HPV sequences in less 
than 10 per cent of cases, a majority of studies rule out 
any role of HPV infection in development of bladder 
cancer92-94. The most significant risk factor associated 
with bladder cancer is smoking; and the carcinogens 
are absorbed through the lungs into the bloodstream, 
where they are filtered out by the kidneys and enter the 
urinary tract. An environmental risk is presented by a 
class of organic chemicals called arylamines. People 
who are in the leather, rubber, printing, and textile 
industries or work with large quantities of paint are 
often exposed to these chemicals chronically and are 
susceptible to developing bladder cancer. 
 In India, carcinoma of urinary bladder is more 
prevalent in men than women. Cancer Registries of 
India show an age standardized rate of uninary bladder 
varies from 2.3 to 5.8 per cent per 100,000 for men and 
0.4 to 1.5 per cent in women. In a study carried out by 
Gopalkrishna et al45 showed presence of HPV16 in 20 
per cent (2/10) cases by PCR. This study showed a small 
but significant probability that HR HPV infection found 
in urinary bladder may be involved in development of 
malignancy at this organ site. 
Stomach cancer: Stomach or gastric cancer can develop 
in any part of the stomach and may spread throughout the 
stomach and to other organs; particularly the esophagus 
and the small intestine. Stomach consists of four 
different layers of cells. The outermost layer is made up 
of epithelial cells which make gland like structures on 
stomach wall. Globally, a large number of studies have 
indicated that most cases of stomach ulcers, gastritis, 
and stomach cancer are caused by Helicobacter pylori 
infection. The association of HPV infection with stomach 
cancer/gastric cancer has been controversial. Some of 
the studies have ruled out presence of HPV in stomach 
cancer95,96, whereas other investigators indicated role of 
HPV 16 in gastric cancer97.
 In India, the number of new stomach cancer cases 
in 2001 was estimated to be approximately 35675 
(n = 23785 in men; 11890 in women)98. The AAR of 
gastric cancer in urban registries (3.0-13.2) is on the 
lower side among those reported worldwide (4.1-95.5). 
It is a disease mainly of males. Gastric cancer is highly 
prevalent among South Indians and it occurs a decade 
earlier as compared with the North Indians99. The 
etiology of gastric cancer is multifactorial and infection 
with Helicobacter pylori has been accepted worldwide 
as the main etiological factor for the development of 
stomach cancer. H. pylori causes carcinogenesis by 
inducing chronic atrophic gastritis, and prevalence of 
its infection is high (49.4 to 83.3%) in India100,101, but 
gastric cancer rates are relatively low. There is no study 
that has focused on the role of HPV in stomach cancer 
in India. Recently, a very low percentage HPV16 
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(8.3%; 2/24) infection in stomach cancer cases has been 
detected30. However, the mechanism of pathogenesis 
and the route of infection of HPV in stomach cancer 
is not clear. The exclusive occurrence of HR HPV type 
16 in stomach cancer from India needs further studies.
Cancer of eye: HPV DNA sequences have been 
reported in benign conditions of the conjuctiva and in 
dysplastic and invasive lesions of the eye also. HPV16 
and 18 E6 gene expression was found in intraepithelial 
neoplasia of the conjuctiva102. However, some authors 
suggest that there is very limited evidence for the 
pathogenesity of HPV in squamous cell carcinoma of 
eye conjuctiva76. In a recent study of retinoblastoma 
specimens no HPV infection could be detected30. 
In a meta-analysis of 65 cases of ocular neoplasia 
comprising 35 papillomas and 30 ocular surface 
squamous neoplasias (OSSN) including 30 normal 
controls, were studied by immunohistochemistry46. 
Interestingly, the results demonstrated 17 per cent HPV 
positivity for conjunctival papillomas but all cases of 
ocular surface squamous neoplasias (OSSN) were 
negative for HPV.  Since majority of retinoblastoma 
is sporadic, it is suggested that this is possibily due to 
inactivation of Rb gene the product of which binds to 
HRHPV E7 protein and the HPV could be transmitted in 
utero during vaginal delivery or otherwise103. Therefore 
it is important to look for prevalence of HPV infection 
in retinoblastoma cases in a larger study. 
Cancer of breast: Breast cancer is the second most 
common cancer in the world, after the cancer of 
the lung, affecting one in eight women during their 
lifetime. It is also the leading cancer among women 
worldwide9. In India, breast cancer is the second most 
common cancer in women and is showing rising trend 
in urban India (NCRP 2005). Various epidemiologic 
risk factors both exogenous as well as endogenous, 
including mutations in breast cancer genes BRCA1 and 
BRCA2104 have been associated with the development 
of breast cancer. Moreover, several oncogeneic viruses 
such as Epstein-Barr Virus (EBV), murine mammary 
tumor virus and HPV have been implicated in the 
development of human breast cancer11. Reports on the 
infection of HPV in Breast cancer are not only limited 
but also controversial. While several studies47,105,106 
have shown that there is complete absence of HPV 
infection in breast cancer; a moderate frequency of 25-
45 per cent HPV infection was reported by many other 
studies worldwide105,107. Recent report on prevalence of 
HPV infection in breast cancer shows 65-85 per cent 
breast cancers positive for HPV DNA11. In view of 
controversial reports, recently a highly sensitive real 
time PCR methodology was employed to screen large 
number of breast cancer specimens but no HPV could 
be detected48.
Benign/Non tumorous lesions 
 The ano-genital warts, skin warts and recurrent 
respiratory papillomatosis are associated with the 
infection of low risk HPVs particularly HPV types 6 
and HPV117,108. Recent studies have established that 
more than 90 per cent of genital warts are caused by 
either HPV6 or HPV11 but studies also show that 
20–50 per cent of lesions may contain co-infections 
with HR HPV types109,110. Genital warts are a highly 
prevalent sexually transmitted disease which affects 
around 1-2 per cent of the sexually active population111. 
As compared to USA, UK, and some other countries 
where robust data are available on the prevalence and 
incidence of genital warts, in India no formal reporting 
system for genital warts is available. Data on the genital 
warts are available only from small epidemiological 
studies carried out randomly using anti-HPV sera-based 
immunostaining112,113, demonstrating presence of HPV 
antigens in 46-83 per cent of genital warts. The presence 
of viral antigen by immunologic test is indicative of 
productive viral infection but not suitable to detect 
latent infections. Thus the positivity represented by 
these studies could be an underestimation. 
 Recurrent respiratory papillomatosis (RRP), 
also known as laryngeal papillomatosis, is a rare 
condition characterized by the recurrent growth 
of benign papillomas in the respiratory tract. The 
papillomas occur anywhere in the respiratory tract 
but most commonly in the larynx108. HPV types 6 and 
11 are the causative agents of almost 100 per cent of 
juvenile onset RRP and adult onset RRP. HPV-11 is 
often associated with more severe form114 which has a 
greater risk of malignant conversion115.  Though sample 
sizes have been very small, sporadic studies from India 
have shown considerable proportions of laryngeal 
papillomas infected with HPV. The HPV infection was 
found to vary from 80 -100 per cent and comprised 
both LR as well as HR-HPV types such as HPV11 and 
HPV16 respectively30,42.
Detection methods and their impact on HPV 
prevalence 
 The prevalence of HPV infection and distribution 
of HPV types at different human organ sites especially 
in cervical and oral precancer and cancer show a 
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considerable variation, whereas in Indian perspective 
the data on HPV prevalence in other organ sites is 
limited. The variations can be partly attributed to 
geographical and ethnic diversity in Indian population 
and partly influenced by the detection techniques 
employed14-16,23,26,27,32,34,37-39,41,49. In India, the prevalence 
of HPV infection has been determined by using 
various techniques which may also the one of the 
potential reason for observed differences (Table II). 
Furthermore, the new emerging technologies for 
HPV DNA testing such as linear array, reverse line 
blot, real time PCR, Luminex bead-based assays and 
microarray chips are more sensitive and have higher 
specificity in addition to detection of multiple HPV 
infections. However, these techniques are expensive, 
labor intensive, require dedicated infrastructure and 
trained manpower. In comparison, immunodetection, 
Southern blot and In situ hybridization, or HCII 
methods have low specificity and sensitivity (Fig.) 
and are gradually getting replaced with advanced 
technology but the data generated using these 
techniques demands revalidation.
 Prevailing data using various HPV tests not only 
show inter-test variations but also susceptible to 
inter- and intra-laboratory variations which is valid 
not only for India but for data available globally. This 
is primarily due to lack of harmonization of HPV 
detection methodologies, differences in sensitivities 
and specificities of the tests, and lack of appropriate 
international standards for HPV detection. This usually 
results in inappropriate judgment of prevailing HPV 
infection and is a major obstacle in surveillance of 
HPV-associated diseases. 
 In addition, studies where multiple HPV infections 
have been investigated26-28 have used some or the other 
hybridization technique which are highly prone to cross 
reactivity and always bear a mark of interrogation which 
can only be resolved by conducting confirmatory type-
specific PCRs and sequencing. These confirmatory 
tests have not been done in majority of the cases in 
India hence the data indicating high degree of multiple 
infections remains questionable. With newly developed 
more sensitive and specific tests, it will be easier to 
delineate and determine the prevalence and type 
distribution of HPV infection more precisely.
Development of international standards (IS)
 In view of tremendous variations in HPV 
prevalence data, World Health Organization (WHO) 
has developed a structured global network of various 
laboratories working in the area of HPV diagnostics 
(HPV LabNet) to improve quality of laboratory 
services for effective surveillance and monitoring 
of HPV vaccination impact.  HPV LabNet has three 
levels, (i) Global reference; (ii) Regional reference; 
and (iii) National/local laboratories based on the 
expertise and capabilities of respective laboratories116. 
The objectives of the network are to provide scientific 
and technical advice, to develop nodal points for 
quality assurance, training and communications 
in HPV diagnostic services. These reference 
laboratories are participating in WHO’s international 
collaborative HPV study coordinated by National 
Institute of Biological Standards and Control, UK 
for establishment of international standards (IS) in 
harmonizing HPV16 and HPV18 DNA Nucleic Acid 
Amplification Technology-based assays which will be 
subsequently transferred to local laboratories. These 
efforts will be immensely important in monitoring 
the impact of HPV vaccination programs worldwide 
and will be of great help for fruitful evaluation of 
data at uniform platform. To extend these efforts, 
HPV laboratories working in India are also getting 
networked under the umbrella of Indian HPV 
Laboratory Consortium. The primary objective of the 
Consortium is to harmonize various HPV detection 
assays and to minimize inter-laboratory variations by 
bringing all the laboratories involved in HPV research 
and diagnostics to a single platform and collectively 
establishing a strong and effective Quality Assurance 
and Quality Control program. 
Impact of HPV vaccine on cervical and other 
cancers
 Despite variations in sensitivities, and 
specificities of various HPV detection technologies 
used to determine the prevalence of HPV in cancers 
of different organ sites, it is well accepted that a 
Fig. Relative sensitivities of HPV nucleic acid detection techniques.
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significant proportions of cancers other than cancer 
of cervix harbor HPV DNA sequences8. As in a 
majority of cases these infections are of high risk 
type, especially HR HPV type 16, it is quite likely 
that HPV oncogenes must be playing an important 
role in the development of cancers at these sites 
too. With the availability of two successful vaccines 
Gardasil (quadrivalent), Cervarix (bivalent) against 
HPV 16, 18, it is expected that a significant number 
of patients bearing such HPV-associated cancers will 
also be benefited by the introduction of these vaccines. 
Therefore, programs designed to study HPV vaccine 
response and post-vaccination surveillance should 
also look into this aspect as secondary end points 
or response indicators of HPV vaccines. Moreover, 
because of almost exclusive occurrence of HPV16 in 
cervical cancer and precancer lesions, it is expected 
that current HPV vaccines which are against HPV16 
and 18 will be much more effective compared to other 
regions of the world where other HR-HPVs are also 
involved in cervical cancers. In addition to above, 
it is also interesting to note that high prevalence of 
HPV16 in penile smears of women harboring HPV16 
positive cervical lesions117 unequivocally advocate 
immunization of male population not only to protect 
them from HPV-associated penile cancer but also to 
augment the herd immunity against HPV in general.  
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